Training: Dentistry, Biomedical Research, Bioengineering, Pathology
Postdoctoral: TGF-beta, wound healing, regeneration, radiation biology, light biology, stem cells, biomaterial, Lasers.
Current: Clinical translational research and molecular mechanism.
Positions: Past-President, NAALT; President-Elect WALT, Co-Chair SPIE, Chair, ASLMS
Interests: Signal Transduction, Lasers, Biological regulation, Photobiomodulation.
Prof. Becker is heading the Department of Translational Oncology at the Westdeutsches Tumorzentrum in Essen with a focus on skin cancer research.
Jürgen C. Becker received his medical degree from the Medical School Hannover for his work on the immune regulatory capacity of natural killer cells on the adaptive immune system. After finishing medical school he was first trained in Dermatology at the University of Würzburg and then as well in Tumor Immunology at the Scripps Research Institute, La Jolla, and the Danish Cancer Society, Copenhagen. For his characterization of the impact of therapeutic interventions on the adaptive immune responses against melanoma in preclinical models he received the PhD in Immunology. In 2003 he became full professor for Dermato-Oncology in Würzburg, where he coordinated a Clinical Research Group focusing on the tumor microenvironment. In 2010, he was appointed as director of General Dermatology at the Medical University of Graz. There, in parallel to his clinical duties, he successfully attracted the FP7 EU-project IMMOMEC (IMmune MOdulating strategies for treatment of MErkel cell Carcinoma, www.immomec.eu) and became deputy speaker of the graduate training program DK-MOLIN (Doktoratskolleg MOLecular fundamentals of INflammation, www.medunigraz.at/DK-MOLIN/).
Regents Professor of Chemistry and Biochemistry at the University of Arizona. Professor of Neuroscience recently inducted into the ACS Hall of Fame and 2011 ACS Goodman Award for Scientific Excellence and Mentorship.
I received my MSc. Degree from Jawaharlal Nehru University, India in 2007 on understanding the role of TBP associated factor 9 (TAF9) in eukaryotic transcription. I completed my Ph.D. training in the laboratory of Prof. Paturu Kondaiah, in 2012, at Indian Institute of Science, Bangalore, India, on exploring the mechanism of precancerous oral lesion (OSF and Oral cancer) using gene expression profiling. I also worked on exploring the molecular mechanism of photo dynamic therapy agents in cancer cells. I did my first post doctorate in Dr. Praveen Arany’s lab at NIDCR, NIH on exploring the role of laser mediated phototoxicity involving ER stress and laser mediated wound healing. I am currently doing my second postdoctoral training in the laboratory of Patricia Steeg at NCI in NIH, on exploring the molecular mechanism of metastasis suppressor gene, NM23 in breast cancer metastasis and its possible therapeutic applications.
Full Professor and Senior Lecturer - Faculty and Nursing and Podiatry, Universidade da Coruña, Spain
Director - Research, Health and Podiatry Unit, Department of Health Sciences, Faculty of Nursing and Podiatry, Universidade da Coruña, Spain
Professor Ralf Paus researches into the biology and pathology of the hair follicle, skin neuroendocrinology, and the science and applications of stem cells residing in human skin.
Director of the Cutaneous Physiopathology Laboratory and Metabolomic Center San Gallicano Dermatological Institute in Rome
Chairman Integrated Center of Metabolomic Research
Member of Italian Commission for Dietetic and Nutrition at the Minister of Health (2006- present)
Member of National Health Council (2007-2010)
Member of the Psocare National Commission supported by the Italian Agency on Drugs (AIFA)
Past President of the European Society for Dermatological Research
Past President of the International Federation of Pigment Cell Societies (IFPCS)
Past President of the European Society of Pigment Cell Research (ESPCR)
Board member of the European Society for Dermatological Research (ESDR)
Member of the European Academy of Dermatology and Venereology (EADV)
Member of the Italian Society of Dermatology and Venereology (SIDEMAST)
Member of the Italian Association of Dermatolgists (ADOI)
Coordinator of the Vitiligo European Task Force
Associate Editor of Pigment Cell Research
Editorial board of PeerJ, Experimental Dermatology, Clinical and Experimental Dermatology
Referee ad hoc for many dermatological journals such as Journal of Investigative Dermatology, British Journal of Dermatology, Journal of EADV, Experimental dermatology, and non dermatological journals such as FASEB J, BBA, J Chromatography, Biochem J, PlOS ONE, Free radical in Biology and Medicine
Author of more than 250 publications and of more than 30 chapters in different books
Dr. Tarl Prow is the Deputy Director of the Dermatology Research Centre within the School of Medicine and heads a group of 10 researchers focused on micromedical devices for dermatology and nanomedicine. He is a multidisciplinary researcher with internationally recognized expertise in the fields of micro-medical device development, nanodermatology, topical drug delivery and non-invasive imaging.
Research focus on tumorimmunology and tumorbiology of skin cancer especially melanoma and merkel cell carcinoma. PhD and Post-Doc at medical university hospital Wuerzburg. Now Associate Professor at Medical University Graz, Austria.
For the past 20 years I have been actively working in the field of melanoma and naevi genomics. I have worked and performed my PhD candidature based at the QIMR Berghofer Medical Research Institute (1999-2015) and in 2015 I relocated as a Research Fellow in the Dermatology Research Centre, The University of Queensland Diamantina Institute. Over this time I have been working towards understanding the aetiology of melanoma, studying gene dysregulation during tumour progression along with predisposition to melanoma in families with high risk for melanoma development. My research group (genomics and miRNA biomarker discovery) based within the Dermatology Research Centre (UQDI) is currently engaged in miRNA biomarker and genomics research for early detection in melanoma, skin cancer (SCC), as well as non-small cell lung cancer.
Desmond Tobin is Professor of Dermatological Science, and Director of the UCD Charles Institute of Dermatology, School of Medicine, University College Dublin, Ireland. EU. Prior he was Professor of Cell Biology & Director of the Centre for Skin Sciences at University of Bradford. He holds a BSc from the National University of Ireland (Maynooth), a PhD from University of London (St. John’s Institute of Dermatology) and post-doc training from New York University Medical School. Over 20y he has researched in basic and applied skin/hair sciences, with a particular focus on the biology of human melanocytes/ pigmentation and hair growth disorders incl. with immune basis.
He was the first to identify antibodies to hair follicle-specific antigens in patients with acute alopecia areata, and first to establish melanocytes from human hair follicles in long-term culture. He has identified a self-similarity of the POMC peptide system in human hair follicle pigmentary unit, how pigmentation can be regulated by CRF/POMC peptides (incl. b-endorphin), and more recently by bone morphogenetic proteins. He revealed an unexpected role for filopodia in melanin transfer under influence of myoxin-X & cdc42. Des is a Fellow of Royal College of Pathologists, Fellow of Royal Society of Biology, and Fellow of Institute of Trichologists (Vice-President). Des serves(ed) on several editorial boards, and has published over 140 publications, incl. 3 books. His H-Index is currently 50.
Dr. Yang’s research focuses on a group of gasotransmitters, especially H2S, in the regulation of cellular functions and human diseases. Dr. Yang has received numerous awards and recognitions, including New Investigator award from the Heart and Stroke Foundation of Canada and Maureen Andrew Award from Heart and Stroke Foundation of Ontario. In his career, Dr. Yang has published ~100 peer-reviewed research articles, some of them published in high-impact journals, including as Science, Circulation, PNAS, and EMBO report etc. Their total citations are 7,481 (September 24, 2018).